Display options
Cite
Yonamine CY, Pinheiro-Machado E, Michalani ML, et al. Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory. Nutr Metab (Lond). 2016;13:44doi: 10.1186/s12986-016-0103-0.
Yonamine, C. Y., Pinheiro-Machado, E., Michalani, M. L., Freitas, H. S., Okamoto, M. M., Corrêa-Giannella, M. L., & Machado, U. F. (2016). Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory. Nutrition & metabolism, 1344. https://doi.org/10.1186/s12986-016-0103-0
Yonamine, Caio Yogi, et al. "Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory." Nutrition & metabolism vol. 13 (2016): 44. doi: https://doi.org/10.1186/s12986-016-0103-0
Yonamine CY, Pinheiro-Machado E, Michalani ML, Freitas HS, Okamoto MM, Corrêa-Giannella ML, Machado UF. Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory. Nutr Metab (Lond). 2016 Jun 29;13:44. doi: 10.1186/s12986-016-0103-0. eCollection 2016. PMID: 27366200; PMCID: PMC4928352.
Copy Download .nbib Format: NLM
Share it on

Nutr Metab (Lond). 2016 Jun 29;13:44. doi: 10.1186/s12986-016-0103-0. eCollection 2016.

Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory.

Nutrition & metabolism

Caio Yogi Yonamine, Erika Pinheiro-Machado, Maria Luiza Michalani, Helayne Soares Freitas, Maristela Mitiko Okamoto, Maria Lucia Corrêa-Giannella, Ubiratan Fabres Machado

Affiliations

  1. Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, 05508-000 São Paulo, SP Brazil.
  2. Laboratory of Medical Investigation 18 (LIM-18) and Cell and Molecular Therapy Center (NUCEL), Medical School, University of São Paulo, São Paulo, Brazil.

PMID: 27366200 PMCID: PMC4928352 DOI: 10.1186/s12986-016-0103-0

Abstract

BACKGROUND: Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.

METHODS: Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1 (SIRT1) activity were analyzed in liver.

RESULTS: Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P < 0.05, DIR vs. DI); besides, it increased (P < 0.01, DIR vs. DI) the hepatic glycogen content, and SIRT1 protein.

CONCLUSIONS: Resveratrol is able to improve glycemic control in insulin-treated T1D-like rats. This effect seems not to involve changes in glucose fluxes in the small intestine, renal proximal tubule, and soleus skeletal muscle; but to be related to several changes in the liver, where downregulation of Slc2a2/GLUT2, Pck1, and G6pc expression was observed, favoring reduction of glucose production and efflux. Besides, resveratrol increased SIRT1 nuclear protein content in liver, which may be related to the observed gene expression regulations.

Keywords: GLUT2; Gluconeogenic enzymes; Glucose transporters; Glycogen; Liver metabolism; SIRT1; Type 1 diabetes

References

  1. Mol Cell Endocrinol. 2005 Jun 15;237(1-2):49-57 - PubMed
  2. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E853-63 - PubMed
  3. Int J Food Sci Nutr. 2015 May;66(3):314-20 - PubMed
  4. Am J Physiol Renal Physiol. 2014 Jan;306(2):F194-204 - PubMed
  5. Lancet. 2014 Mar 22;383(9922):1068-83 - PubMed
  6. Can J Physiol Pharmacol. 2012 Feb;90(2):237-42 - PubMed
  7. Food Chem Toxicol. 2013 Nov;61:112-20 - PubMed
  8. Med Clin North Am. 2004 Jul;88(4):787-835, ix - PubMed
  9. N Engl J Med. 1999 Jul 22;341(4):248-57 - PubMed
  10. J Biol Chem. 2005 May 27;280(21):20589-95 - PubMed
  11. Expert Opin Emerg Drugs. 2014 Mar;19(1):5-9 - PubMed
  12. Biochim Biophys Acta. 2015 Jun;1852(6):1145-54 - PubMed
  13. Biochem Mol Biol Int. 1995 Sep;37(1):33-8 - PubMed
  14. Eur J Pediatr. 1998 Oct;157(10):783-97 - PubMed
  15. Biol Pharm Bull. 2008 May;31(5):897-902 - PubMed
  16. Best Pract Res Clin Endocrinol Metab. 2003 Sep;17(3):365-83 - PubMed
  17. Pharmacogenomics. 2013 Jun;14(8):847-50 - PubMed
  18. Diabetologia. 2008 Feb;51(2):216-26 - PubMed
  19. Mol Aspects Med. 2013 Apr-Jun;34(2-3):183-96 - PubMed
  20. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12861-6 - PubMed
  21. Horm Metab Res. 1993 Sep;25(9):462-5 - PubMed
  22. Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E141-5 - PubMed
  23. Nat Rev Endocrinol. 2010 Jun;6(6):326-34 - PubMed
  24. Diabetol Metab Syndr. 2014 Sep 10;6(1):97 - PubMed
  25. Mol Aspects Med. 2015 Dec;46:21-33 - PubMed
  26. Life Sci. 2013 Nov 19;93(22):805-13 - PubMed
  27. Diabetes Obes Metab. 2013 Aug;15(8):701-12 - PubMed
  28. Can J Physiol Pharmacol. 2012 May;90(5):537-45 - PubMed
  29. Expert Opin Pharmacother. 2015;16(15):2331-41 - PubMed
  30. J Biol Chem. 2001 Nov 16;276(46):42812-7 - PubMed
  31. Pediatr Endocrinol Rev. 2015 Mar;12(3):266-82 - PubMed
  32. Endocrinology. 2008 Feb;149(2):717-24 - PubMed
  33. Mol Cell Endocrinol. 2013 May 6;370(1-2):87-95 - PubMed
  34. Biochem Biophys Res Commun. 2012 Jun 8;422(3):469-75 - PubMed
  35. Med Clin North Am. 2015 Jan;99(1):1-16 - PubMed
  36. Diabetologia. 2015 Feb;58(2):221-32 - PubMed
  37. Molecules. 2014 Nov 14;19(11):18632-55 - PubMed
  38. Life Sci. 2007 Apr 10;80(18):1713-20 - PubMed
  39. Chem Biol Interact. 2009 May 15;179(2-3):356-62 - PubMed
  40. Diabetes Res Clin Pract. 2012 Sep;97(3):474-82 - PubMed
  41. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E685-92 - PubMed
  42. Eur J Pharmacol. 2013 Nov 15;720(1-3):147-57 - PubMed
  43. World J Diabetes. 2015 Dec 10;6(17):1323-36 - PubMed
  44. Pediatr Diabetes. 2016 Dec;17 (8):545-558 - PubMed
  45. Mol Nutr Food Res. 2012 Aug;56(8):1282-91 - PubMed
  46. Gene. 2015 Oct 10;570(2):213-20 - PubMed
  47. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G241-8 - PubMed
  48. J Pharm Pract. 2016 Apr;29(2):144-59 - PubMed
  49. Mol Cell Biochem. 2014 Aug;393(1-2):111-22 - PubMed
  50. J Endocrinol. 2011 Oct;211(1):55-64 - PubMed
  51. Nutr Metab (Lond). 2015 Dec 23;12:60 - PubMed

Publication Types